Corporate Milestones

1983 The Binding Site Ltd was founded and launched with a range of highly specific polyclonal antisera used by clinical researchers worldwide.
1987 IgG Subclass RID kits first launched for the investigation of immunodeficiency.
1988 The Binding Site Inc in San Diego, USA was founded, the product range and customer base for clinical research antibodies continued to grow.
1990 First FDA cleared commercially available human IgG subclass kits for routine automated clinical use launched.
1992 Received Queen's Award for Export Achievement
1993 The Binding Site GmbH in Heidelberg, Germany founded. Dominance achieved worldwide of the human IgG subclass testing market.
1996 The Binding Site France founded in Grenoble.
2001 The Binding Site Inc sign deal with Dynex technologies for distribution of their DSX fully automated EIA processor.
2001 First publication highlighting the clinical significance of Freelite in nonsecretory multiple myeloma patients is published in Blood.
2003 Publication highlighting the clinical utility of Freelite for the replacement of Bence Jones protein in The Lancet.
2004 First National guidelines for the incorporation of Freelite assays into the management of Primary Amyloidosis patients published in the British Journal of Haematology.
2006 Freelite incorporated into the National UK guidelines for the diagnosis and monitoring of Multiple Myeloma published in the British Journal of Haematology
2006 Mayo Clinic publish the first independent study in the USA recommending Freelite as a routine screening test in Mayo Clinic Proceedings.
2007 Number of DSX processors placed by The Binding Site in the USA reaches 150.
2007 The Binding Site Spain founded in Barcelona.
2007 Won Queen's Award for Enterprise in the category Innovation, for the Freelite serum free light chain assay
2007 Journal of the American Society of Nephrology publishes the first study using Haemodialysis for the removal of serum free light chains as measured by Freelite.